DT Investment Partners LLC raised its stake in Sanofi SA (NYSE:SNY) by 6.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,933 shares of the company’s stock after acquiring an additional 5,487 shares during the quarter. DT Investment Partners LLC’s holdings in Sanofi were worth $4,352,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Ibex Wealth Advisors acquired a new stake in shares of Sanofi during the 2nd quarter worth approximately $25,000. Heritage Wealth Advisors grew its position in shares of Sanofi by 141.2% during the 2nd quarter. Heritage Wealth Advisors now owns 603 shares of the company’s stock worth $26,000 after buying an additional 353 shares during the period. Bessemer Group Inc. grew its position in shares of Sanofi by 292.4% during the 2nd quarter. Bessemer Group Inc. now owns 671 shares of the company’s stock worth $29,000 after buying an additional 500 shares during the period. Prestige Wealth Management Group LLC acquired a new stake in shares of Sanofi during the 2nd quarter worth approximately $37,000. Finally, Evolution Wealth Advisors LLC acquired a new stake in shares of Sanofi during the 2nd quarter worth approximately $40,000. Hedge funds and other institutional investors own 7.04% of the company’s stock.
In related news, major shareholder Sanofi sold 172,904 shares of Sanofi stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $281.15, for a total transaction of $48,611,959.60. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.00% of the stock is owned by company insiders.
Sanofi stock opened at $45.86 on Friday. The company’s 50 day simple moving average is $45.85 and its 200 day simple moving average is $43.37. Sanofi SA has a fifty-two week low of $40.00 and a fifty-two week high of $47.47. The firm has a market capitalization of $114.86 billion, a price-to-earnings ratio of 14.65, a PEG ratio of 2.41 and a beta of 0.67. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Recommended Story: What is Green Investing?
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.